

LIFE SCIENCES BUSINESS

Performance Overview

Revenue

42.9 billion yen
↑ **+12.5%**

- The Life Sciences Business posted a year-on-year increase in segment revenue on the back of higher sales of diagnostic reagent materials, in addition to increased sales volume by KBI Biopharma, Inc. (KBI), a Group company.

However, operating profit remained mostly unchanged, largely because of additional upfront capital investments targeting future expansion of this business segment.

Life Sciences as a New Business Pillar

In the Life Sciences Business, which has grown to become the third pillar of JSR Group's businesses, we established a system capable of providing integrated support for all processes, from antibody drug discovery to manufacturing. In addition to two companies that are already Group members, KBI Biopharma, Inc. and Medical & Biological Laboratories Co., Ltd. (MBL), we acquired two other companies in this business: Switzerland-based Selexis SA, which has a technology in quickly generating cell lines used to culture antibodies efficiently, and U.S.-based Crown Bioscience International, a provider of preclinical drug discovery and development support services. Accordingly, we now have an integrated system in place to support all processes, from antibody drug discovery to manufacturing. All Group companies involved in the Life Sciences Business will unite in an effort to expand our bio-pharmaceutical discovery support business. Our aim is to provide services that improve the probability of success in the drug discovery process for antibody drugs and shorten the development period.

To address demand for commercial-level manufacturing, KBI completed an upgrade of its facilities at the end of 2017 and has started rolling out production. In the first half of 2018, we launched analytical services at a base established on the premises of JSR Micro NV in Europe. In addition, we started commercial production at new manufacturing facilities, also established on NV's premises, to address expected growth in demand from the increased adoption of Amsphere™ A3, chromatography resin for refining use.

Meanwhile, we recently established the JSR-Keio University Medical and Chemical Innovation Center (JKiC) in research alliance with Keio University and Keio University Hospital. Through this industry-academia collaboration, we will work to develop innovative materials and products that support advancements in new medical fields, with the aim of expanding our Life Sciences Business into the future.

We will provide innovative services, products, and materials to pharmaceutical companies, biotechnology companies, and academia covering the entire development process for new medical treatments.

